dalteparin and apixaban

dalteparin has been researched along with apixaban in 112 studies

Research

Studies (112)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (2.68)	29.6817
2010's	71 (63.39)	24.3611
2020's	38 (33.93)	2.80

Authors

Authors	Studies
Ansell, J; Davidson, BL; Deitchman, D; Gallus, A; Lassen, MR; Pineo, G	1
Chen, D; Gallus, A; Lassen, MR; Pineo, G; Portman, RJ; Raskob, GE	1
Gómez-Outes, A; Pozo-Hernández, C; Suárez-Gea, ML	1
Fareed, J; Hull, R	1
Chen, D; Gallus, A; Hornick, P; Lassen, MR; Pineo, G; Raskob, GE	1
Nwachukwu, U	1
Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L	1
Cao, Y; Gao, F; Huang, J; Liao, C; Wu, L	1
Chen, D; Gallus, A; Lassen, MR; Pineo, G; Ramirez, LM; Raskob, GE	1
Hylek, EM	1
Jameson, SS; Reed, MR; Sanders, RD	1
Fadda, V; Maratea, D; Messori, A; Trippoli, S	1
Friedman, RJ	1
Goldhaber, SZ; Haas, SK; Kakkar, AK; Knabb, RM; Leizorovicz, A; Merli, G; Weitz, JI	1
Einecke, D	1
Migliaccio-Walle, K; Rublee, D; Simon, TA	1
Chen, D; Gallus, AS; Lassen, MR; Pineo, GF; Ramirez, LM; Raskob, GE; Wright, RT	1
Barrett, YC; Frost, C; Lacreta, F; Pursley, J; Song, Y; Wang, J; Wastall, P; Wright, R	1
Espada, NG; González, TC; Merino, RG; Nieto, JA	1
Gallerani, M; Imberti, D; Manfredini, R	1
Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E	1
Li, XM; Sun, SG; Zhang, WD	1
Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C	1
Chen, D; Gallus, AS; Lassen, MR; Pineo, GF; Ramacciotti, E; Ramirez, LM; Raskob, GE; Wang, L	1
Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C	1
Abe, K; Conley, PB; DeGuzman, FR; Hollenbach, SJ; Hutchaleelaha, A; Inagaki, M; Karbarz, MJ; Lee, G; Lu, G; Luan, P; Phillips, DR; Sinha, U	1
Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK	1
Klein, HH	1
Agnelli, G; Buller, HR; Cohen, A; Curto, M; Gallus, AS; Johnson, M; Masiukiewicz, U; Pak, R; Raskob, GE; Thompson, J; Weitz, JI	1
Accassat, S; Bertoletti, L; Décousus, H; Lega, JC; Merah, A; Mismetti, P	1
El-Hadi, W; Kadambi, A; Patterson, J; Raymond, V; Revankar, N	1
Cohen, AA; Rider, T	1
Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD	1
Gupta, K; Singh, D; Vacek, JL	1
Avendaño-Solá, C; Gómez-Outes, A; Terleira-Fernández, AI; Vargas-Castrillón, E	1
Benedetti, R; Caforio, M; Imberti, D; Maniscalco, P; Porcellini, G	1
Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM	1
Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R	1
Cattaneo, M; Lussana, F; Squizzato, A	1
Kathmann, W	1
Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA	1
Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T	1
Elalamy, I; Gerotziafas, GT; Larsen, A; Mbemba, E; Rousseau, A; Van Dreden, P	1
Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Thompson, J	1
Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI	1
Le, HH; Moshyk, A; Mtibaa, M; Quon, P; Raymond, V	1
Francart, S; Francis, CW; Gosselin, RC; Gudmundsdottir, BR; Hawes, E; Letertre, LR; Malmstrom, RE; Moll, S; Onundarson, PT; Skeppholm, M	1
Dickison, DM; King, DA; Pow, RE; Vale, PR	1
Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E	1
Gu, X; Lin, H; Wu, B; Yan, X; Zhou, L	1
Agnelli, G; Bleker, SM; Büller, HR; Cohen, AT; Curto, M; Gallus, AS; Middeldorp, S; Raskob, GE; Sisson, M; Weitz, JI	1
Garnock-Jones, KP; Greig, SL	1
Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT	1
Gu, X; Lin, H; Wu, B; Xu, Z; Yan, X	1
Adelmeijer, J; Bos, S; Boyett, SL; Daita, K; Lisman, T; Potze, W; Sanyal, AJ; Siddiqui, MS	1
Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C	1
Chi, G; Cohen, AT; Curnutte, JT; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Kittelson, JM; Turpie, AGG	1
Chen, X; Jin, Y; Wang, Z; Xiang, Y; Zhao, Y; Zheng, J	1
Ashrani, A; Henkin, S; Le-Rademacher, JG; Lenz, CJ; Leon Ferre, RA; Loprinzi, CL; McBane Ii, R; Perez-Botero, J; Wysokinski, WE	1
Cohen, DA; Thind, M	1
Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX	1
Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E	1
Grübler, B	1
Azboy, I; Groff, H; Parvizi, J	1
Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G	1
Abdel-Latif, A; Bhalla, M; Bhalla, V; Smyth, SS; Williams, MV; Ziada, K	1
Abreu de Sousa, J; Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Torbicki, A; Verso, M; Vescovo, G	1
Lou, XJ; Shan, P; Yang, X; Yu, Z	1
Deitelzweig, S; Guo, JD; Gupta, A; Hlavacek, P; Lin, J; Lingohr-Smith, M; Mardekian, J; Marshall, A; Menges, B; Nadkarni, A; Pan, X; Rosenblatt, L; Wygant, G	1
Broderick, C; Fortes Villas Boas, PJ; Nunes-Nogueira, VS; Yoo, HH	1
Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J	1
Alpert, JS; Dalen, JE; Jaswal, N; Plitt, JL; Stein, PD	1
Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE	1
Batakji, M; Theodore, D	1
Anderson, D; Ashrani, A; Gundabolu, K; Henkin, S; Houghton, DE; Kuzma, C; Le-Rademacher, JG; Lenz, CJ; Leon Ferre, RA; Loprinzi, CL; McBane, RD; Perepu, U; Perez Botero, J; Tafur, A; Vishnu, P; Wysokinski, WE; Zemla, T	1
Aungraheeta, R; FitzGibbon, L; Mumford, AD; Reilly-Stitt, C	1
Bautista, M; Bonilla, G; Castro, J; Llinás, A; Moreno, JP	1
Auñón-Chancellor, SM; Moll, S; Pattarini, JM; Sargsyan, A	1
Bauersachs, R; Becker, B; Berkowitz, SD; Freitas, MCS; Lassen, MR; Metzig, C; Raskob, GE; Weitz, JI	1
Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G	1
Singh Lubana, S; Singh, N; Tsai, HM	1
Abuarqoub, A; Akel, T; Qaqa, F; Shamoon, F	1
Diver, E	1
Babayan, LM; Behbakht, K; Breed, CA; Brennecke, A; Cheng, G; Corr, BR; Flink, D; Guntupalli, SR; Lefkowits, C; Matsuo, K; Ramzan, AA; Sheeder, J; Tayebnejad, A; Wheeler, LJ	1
Brennecke, A; Glickman, A; Guntupalli, SR; Ross, ME; Tayebnejad, A	1
Ebner, M; Lankeit, M	1
Biousse, V; Bose, S; Dumitrascu, OM; Lyden, PD; Volod, O; Wang, Y	1
Levesque, H; Miranda, S	1
Badgett, RG; Marshall, AL; Riaz, IB	1
Brennecke, A; Glickman, A; Guntupalli, SR; Matsuo, K; Sheeder, J; Tayebnejad, A	1
Bhatt, HV; Derr, K; Ghia, S; Katz, D; Lazar, M; Narula, J; Tomey, MI	1
Algaby, AZ; Hassan, A; Mokadem, ME	1
Barouqa, M; Bellin, E; Billett, HH; Golestaneh, L; Gonzalez-Lugo, JD; Ikemura, K; Kushnir, M; Lo, Y; Rahman, S; Reyes-Gil, M; Stahl, LR; Szymanski, J	1
Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC	1
Feng, W; Huang, D; Lu, A; Wang, X	1
Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH	1
Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G	1
Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J	1
Banerjee, S; Elhence, A; Garg, PK; Kunal, K	1
Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A	1
Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE	1
Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A	1
Bagiella, E; Ben-Yehuda, O; Bustamante, J; Dressler, O; Farkouh, ME; Fuster, V; Godoy, LC; Granada, C; Granada, JF; Lala, A; Moreno, PR; Nadkarni, GN; Palacios, IF; Peyra, C; Stone, GW; Tinuoye, EO	1
Cakir, A; Cekmez, Y; Gurkan, K; Kopuk, SY; Ozer, N	1
Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S	1
Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I	1
Bree, KK; Casteel, KN; Gonzalez, MG; Gregg, JR; Kukreja, JB; Mantaring, C; Matin, SF; Msaouel, P; Rukundo, I; Westerman, ME	1
Fredenburgh, JC; Guan, Z; Hussain, RH; Jaffer, IH; Wang, R; Weitz, JI	1
Covens, A; Geerts, W; Gien, LT; Kupets, R; Lin, Y; Spénard, E; Vicus, D	1
Attalla, K; Elkun, Y; Geduldig, J; Lavallee, E; Mehrazin, R; Rich, JM; Sfakianos, JP; Wiklund, P	1
Arce-Huamani, MA; Barboza, JJ; Maguiña, JL; Martínez-Herrera, JF; Torres-Roman, JS	1

Reviews

27 review(s) available for dalteparin and apixaban

Article	Year
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thrombosis and haemostasis, 2011, Volume: 105, Issue:2 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Evidence-Based Medicine; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Odds Ratio; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism	2011
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:9 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics, 2011, Volume: 34, Issue:10 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2011
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. The Journal of bone and joint surgery. British volume, 2012, Volume: 94, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Male; Middle Aged; Perioperative Care; Postoperative Hemorrhage; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Venous Thromboembolism	2012
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ (Clinical research ed.), 2012, Jun-14, Volume: 344 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Chinese medical journal, 2012, Volume: 125, Issue:13 Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Venous Thromboembolism	2012
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thrombosis and haemostasis, 2012, Volume: 108, Issue:5 Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire international, 2012, Volume: 21, Issue:130 Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interactions; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism	2012
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison. Chest, 2013, Volume: 144, Issue:2 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
NOACs for thromboprophylaxis in medical patients. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin	2013
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. The journal of trauma and acute care surgery, 2013, Volume: 75, Issue:3 Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin	2013
Anticoagulation and antiplatelet therapy in acute coronary syndromes. Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2014
Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2015, Volume: 21, Issue:2 Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Enoxaparin; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Venous Thromboembolism	2015
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. Thrombosis research, 2015, Volume: 135, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis	2015
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty. Thrombosis and haemostasis, 2015, Volume: 114, Issue:2 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Postoperative Complications; Postoperative Hemorrhage; Prothrombin; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome	2015
Apixaban: A Review in Venous Thromboembolism. Drugs, 2016, Volume: 76, Issue:15 Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin	2016
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. The Journal of arthroplasty, 2017, Volume: 32, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2017
Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 42, Issue:5 Topics: Anticoagulants; Aspirin; Databases, Factual; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Joint Diseases; Odds Ratio; Postoperative Complications; Pyrazoles; Pyridones; Venous Thromboembolism	2017
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine, 2017, Volume: 96, Issue:40 Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin	2017
Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients. The American journal of cardiology, 2018, 10-01, Volume: 122, Issue:7 Topics: Administration, Oral; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Hospitalization; Humans; Pyrazoles; Pyridones; Venous Thromboembolism	2018
Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis. Bioscience reports, 2018, 12-21, Volume: 38, Issue:6 Topics: Anticoagulants; Arthroplasty; Enoxaparin; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2018
Outpatient versus inpatient treatment for acute pulmonary embolism. The Cochrane database of systematic reviews, 2019, 03-06, Volume: 3 Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; Hospitalization; Humans; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban	2019
Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. Pharmacological research, 2021, Volume: 166 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism	2021
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. Medicine, 2021, Mar-19, Volume: 100, Issue:11 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2021
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2022, 03-08, Volume: 79, Issue:9 Topics: Anticoagulants; COVID-19; Critical Care; Enoxaparin; Hospitalization; Humans; Pyrazoles; Pyridones; Thromboembolism; Thrombosis	2022
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Medicina (Kaunas, Lithuania), 2023, Oct-20, Volume: 59, Issue:10 Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism	2023

Trials

28 trial(s) available for dalteparin and apixaban

Article	Year
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:12 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Argentina; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Europe; Factor Xa; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Israel; Male; Middle Aged; North America; Pyrazoles; Pyridones; Risk Assessment; South Australia; Treatment Outcome; Venous Thromboembolism; Warfarin	2007
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. The New England journal of medicine, 2009, Aug-06, Volume: 361, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Care; Postoperative Complications; Pyrazoles; Pyridones; Venous Thromboembolism	2009
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (London, England), 2010, Mar-06, Volume: 375, Issue:9717 Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Venous Thromboembolism	2010
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Confidence Intervals; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Treatment Outcome; Venous Thromboembolism; Young Adult	2010
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Respiratory Insufficiency; Risk Factors; Treatment Outcome; Venous Thromboembolism	2011
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thrombosis and haemostasis, 2012, Volume: 107, Issue:5 Topics: Administration, Oral; Adult; Anticoagulants; Blood Coagulation; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Substitution; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneous; International Normalized Ratio; Male; Middle Aged; New Jersey; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones	2012
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thrombosis research, 2012, Volume: 130, Issue:2 Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2012
Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:2 Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Venous Thromboembolism	2012
Oral apixaban for the treatment of acute venous thromboembolism. The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9 Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazoles; Pyridones; Treatment Outcome; Venous Thromboembolism; Warfarin	2013
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:12 Topics: Aged; Anticoagulants; Chi-Square Distribution; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin	2015
Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. Journal of the American Heart Association, 2015, Dec-01, Volume: 4, Issue:12 Topics: Aged; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Proportional Hazards Models; Pulmonary Embolism; Pyrazoles; Pyridones; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis; Warfarin	2015
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and haemostasis, 2016, Volume: 115, Issue:4 Topics: Adult; Aged; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk; Treatment Outcome; Venous Thromboembolism; Warfarin	2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12 Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Infusions, Intravenous; Intracranial Hemorrhages; Male; Prospective Studies; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thrombosis	2016
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thrombosis and haemostasis, 2016, Nov-30, Volume: 116, Issue:6 Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin	2016
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10 Topics: Anticoagulants; Canada; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Neoplasms; Pyrazoles; Pyridones; Recurrence; Risk Factors; Time Factors; Treatment Outcome; United States; Venous Thromboembolism	2017
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thrombosis and haemostasis, 2018, Volume: 118, Issue:9 Topics: Acute Disease; Administration, Oral; Adult; Anticoagulants; Dalteparin; Europe; Follow-Up Studies; Humans; Neoplasms; Prospective Studies; Pyrazoles; Pyridones; Treatment Outcome; United States; Venous Thromboembolism	2018
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. American journal of hematology, 2019, Volume: 94, Issue:11 Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Propensity Score; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Analysis; Treatment Outcome; Venous Thromboembolism	2019
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis : JTH, 2020, Volume: 18, Issue:2 Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outcome; Venous Thromboembolism	2020
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA, 2020, 01-14, Volume: 323, Issue:2 Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Care; Pulmonary Embolism; Pyrazoles; Pyridones; Single-Blind Method; Venous Thromboembolism; Venous Thrombosis	2020
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. The New England journal of medicine, 2020, 04-23, Volume: 382, Issue:17 Topics: Administration, Oral; Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Incidence; Injections, Subcutaneous; Intention to Treat Analysis; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Pulmonary Embolism; Pyrazoles; Pyridones; Secondary Prevention; Single-Blind Method; Venous Thromboembolism; Venous Thrombosis	2020
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA network open, 2020, 06-01, Volume: 3, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, Female; Gynecologic Surgical Procedures; Humans; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Quality of Life; Venous Thromboembolism; Young Adult	2020
Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery. Gynecologic oncology, 2020, Volume: 159, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Decision Support Techniques; Enoxaparin; Female; Fibrinolytic Agents; Genital Neoplasms, Female; Humans; Middle Aged; Postoperative Hemorrhage; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Venous Thromboembolism	2020
Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular, 2021, Volume: 29, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Egypt; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridones; Time Factors; Treatment Outcome; Venous Thrombosis	2021
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis, 2021, Volume: 121, Issue:5 Topics: Aged; Dalteparin; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Gastrointestinal Neoplasms; Hemorrhage; Humans; Incidence; Italy; Male; Middle Aged; Pyrazoles; Pyridones; Survival Analysis; Venous Thromboembolism	2021
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European journal of cancer (Oxford, England : 1990), 2021, Volume: 148 Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Drug Therapy, Combination; Equivalence Trials as Topic; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Pyrazoles; Pyridones; Venous Thromboembolism	2021
Apixaban or enoxaparin: Which is better for thromboprophylaxis after total hip and total knee arthroplasty in Indian patients? British journal of clinical pharmacology, 2022, Volume: 88, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Pyrazoles; Pyridones; Venous Thromboembolism	2022
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial Haematologica, 2022, 07-01, Volume: 107, Issue:7 Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Kidney; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembolism	2022
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. Thrombosis and haemostasis, 2022, Volume: 122, Issue:5 Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembolism	2022

Other Studies

57 other study(ies) available for dalteparin and apixaban

Article	Year
Apixaban or enoxaparin for thromboprophylaxis. The New England journal of medicine, 2009, Nov-19, Volume: 361, Issue:21 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Risk; Venous Thromboembolism	2009
Apixaban to prevent venous thromboembolism after knee replacement. Lancet (London, England), 2010, Mar-06, Volume: 375, Issue:9717 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Fibrinolytic Agents; Humans; Postoperative Complications; Pyrazoles; Pyridones; Venous Thromboembolism	2010
Health trends. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2010, Volume: 25, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Diabetes Mellitus, Type 2; Diphosphonates; Drug Therapy; Dyslipidemias; Enoxaparin; Fibrinolytic Agents; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Imidazoles; Middle Aged; Neoplasm Staging; Pharmacy; Pyrazoles; Pyridones; Salicylates; Treatment Outcome; Venous Thromboembolism; Young Adult; Zoledronic Acid	2010
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clinical pharmacology and therapeutics, 2010, Volume: 88, Issue:3 Topics: Aged; Area Under Curve; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kidney Diseases; Male; Models, Biological; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin	2010
Therapeutic potential of oral factor Xa inhibitors. The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26 Topics: Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2010
Apixaban vs. enoxaparin after hip replacement. The New England journal of medicine, 2011, 03-24, Volume: 364, Issue:12 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hemorrhage; Humans; Outcome Assessment, Health Care; Postoperative Complications; Pyrazoles; Pyridones; Research Design; Venous Thromboembolism	2011
[ADOPT study. Longer thrombosis prevention in internal medicine patients has no advantage]. MMW Fortschritte der Medizin, 2011, Dec-01, Volume: 153, Issue:48 Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Enoxaparin; Humans; Injections, Subcutaneous; Internal Medicine; Length of Stay; Long-Term Care; Patient Discharge; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Thromboembolism	2011
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach. Postgraduate medicine, 2012, Volume: 124, Issue:1 Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism	2012
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:3 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biomarkers; Body Mass Index; Body Weight; Chi-Square Distribution; Clinical Trials, Phase III as Topic; Creatinine; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sex Factors; Treatment Outcome; Venous Thromboembolism	2013
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. Revista espanola de salud publica, 2012, Volume: 86, Issue:6 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism	2012
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature medicine, 2013, Volume: 19, Issue:4 Topics: Animals; Anticoagulants; Antidotes; Benzamides; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostasis; Male; Mice; Mice, Inbred C57BL; Morpholines; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rabbits; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Rivaroxaban; Thiophenes	2013
[Thromboprophylaxis in medical patients: Which modifications with the new oral anticoagulants?]. Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:9 Pt 1 Topics: Administration, Oral; Anticoagulants; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism	2013
A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgraduate medicine, 2013, Volume: 125, Issue:4 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Decision Trees; Drug Administration Schedule; Enoxaparin; Female; Health Care Costs; Humans; Male; Markov Chains; Models, Economic; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Venous Thromboembolism	2013
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. PharmacoEconomics, 2014, Volume: 32, Issue:9 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; Decision Trees; Economics, Pharmaceutical; Enoxaparin; Models, Economic; Pyrazoles; Pyridones; Rivaroxaban; Spain; Treatment Outcome; Venous Thromboembolism	2014
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. The American journal of gastroenterology, 2015, Volume: 110, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment	2015
[Prevention with lower bleeding risk]. MMW Fortschritte der Medizin, 2015, Apr-02, Volume: 157, Issue:6 Topics: Adult; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Thromboembolism	2015
The evolving role of dabigatran etexilate in clinical practice. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13 Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism	2015
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. Thrombosis research, 2015, Volume: 136, Issue:6 Topics: Anticoagulants; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Enoxaparin; Factor Xa; Female; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Inhibitory Concentration 50; MCF-7 Cells; Pancreatic Neoplasms; Polysaccharides; Pyrazoles; Pyridones; Thrombin; Thrombosis	2015
Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Journal of medical economics, 2016, Volume: 19, Issue:6 Topics: Anticoagulants; Canada; Cost-Benefit Analysis; Enoxaparin; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Markov Chains; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Venous Thromboembolism; Warfarin	2016
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:5 Topics: Anticoagulants; Blood Coagulation Tests; Blood Donors; Calibration; Dabigatran; Enoxaparin; Factor X; Female; Fondaparinux; Heparin; Humans; International Normalized Ratio; Male; Polysaccharides; Prothrombin; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thromboplastin; Warfarin	2016
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. Internal medicine journal, 2016, Volume: 46, Issue:9 Topics: Aged; Arthroplasty, Replacement, Knee; Australia; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Venous Thromboembolism	2016
Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. Clinical drug investigation, 2016, Volume: 36, Issue:12 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; China; Cost-Benefit Analysis; Decision Trees; Enoxaparin; Humans; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Venous Thromboembolism	2016
Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. Advances in therapy, 2017, Volume: 34, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; China; Cost-Benefit Analysis; Decision Trees; Enoxaparin; Humans; Long Term Adverse Effects; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2017
Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. Thrombosis research, 2017, Volume: 150 Topics: Adult; Alcoholism; Anticoagulants; Dabigatran; Enoxaparin; Female; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazoles; Pyridones; Thrombosis	2017
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:7 Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridones; Recurrence; Retrospective Studies; Rivaroxaban; Secondary Prevention; Venous Thromboembolism; Warfarin	2018
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10 Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hospitalization; Humans; Multivariate Analysis; Nonlinear Dynamics; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism	2017
Pulmonary Embolism Presenting as Persistent Hiccups. The American journal of medicine, 2018, Volume: 131, Issue:2 Topics: Anticoagulants; Baclofen; Computed Tomography Angiography; Elective Surgical Procedures; Enoxaparin; Hiccup; Humans; Male; Middle Aged; Muscle Relaxants, Central; Patellar Ligament; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Time Factors	2018
Anticoagulation prescribing patterns in patients with cancer. Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle Aged; Neoplasms; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Treatment Outcome; Venous Thromboembolism; Warfarin	2018
Hamostaseologie, 2018, Volume: 38, Issue:1 Topics: Clinical Trials, Phase III as Topic; Enoxaparin; Germany; Guideline Adherence; Humans; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Survival Analysis; Venous Thrombosis; Warfarin	2018
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. The Journal of arthroplasty, 2018, Volume: 33, Issue:11 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin	2018
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:9 Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis	2018
Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:9_suppl Topics: Adolescent; Adult; Aged; Costs and Cost Analysis; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; United States; Venous Thromboembolism; Warfarin	2018
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. Vascular pharmacology, 2019, Volume: 120 Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K	2019
Extended Thromboprophylaxis for Medical Patients. The American journal of medicine, 2020, Volume: 133, Issue:1 Topics: Aftercare; Anticoagulants; Benzamides; Duration of Therapy; Enoxaparin; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Length of Stay; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis	2020
Hemorrhagic Shock After Lumbar Puncture. Neurocritical care, 2019, Volume: 31, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Central Nervous System Diseases; Computed Tomography Angiography; Enoxaparin; Erythrocyte Transfusion; Factor VIII; Factor Xa Inhibitors; Female; Fibrinogen; Fluid Therapy; Heparin; Humans; Middle Aged; Plasma; Postoperative Complications; Pyrazoles; Pyridones; Radiology, Interventional; Retroperitoneal Space; Sarcoidosis; Shock, Hemorrhagic; Spinal Puncture	2019
Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays. International journal of laboratory hematology, 2020, Volume: 42, Issue:2 Topics: Blood Coagulation Tests; Enoxaparin; Factor Xa Inhibitors; Humans; Plasma; Protein C; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thrombin	2020
Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study. International orthopaedics, 2020, Volume: 44, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Drug Administration Routes; Enoxaparin; Female; Hip Fractures; Humans; Injections, Subcutaneous; Male; Medication Adherence; Middle Aged; Osteoarthritis; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Young Adult	2020
Venous Thrombosis during Spaceflight. The New England journal of medicine, 2020, 01-02, Volume: 382, Issue:1 Topics: Aerospace Medicine; Anticoagulants; Drug Administration Schedule; Enoxaparin; Humans; Jugular Veins; Pyrazoles; Pyridones; Space Flight; Telemedicine; Ultrasonography; Venous Thrombosis; Weightlessness	2020
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia. The American journal of case reports, 2020, May-29, Volume: 21 Topics: Aged; Antithrombins; Arginine; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pipecolic Acids; Pyrazoles; Pyridones; ST Elevation Myocardial Infarction; Sulfonamides; Thrombocytopenia; Thrombosis	2020
Pulmonary embolism: A complication of COVID 19 infection. Thrombosis research, 2020, Volume: 193 Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Tissue Plasminogen Activator	2020
Apixaban vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous Thromboembolism. JAMA network open, 2020, 06-01, Volume: 3, Issue:6 Topics: Enoxaparin; Female; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembolism	2020
Adherence to postoperative thromboprophylactic medication among gynecologic oncology patients: A subanalysis. Gynecologic oncology, 2020, Volume: 158, Issue:3 Topics: Aged; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, Female; Humans; Medication Adherence; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Venous Thrombosis	2020
[Antithrombotic Treatment of Pulmonary Embolism]. Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:14 Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinolytic Agents; Fondaparinux; Guideline Adherence; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles	2020
Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:8 Topics: Arterial Occlusive Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Substitution; Enoxaparin; Factor Xa Inhibitors; Host Microbial Interactions; Humans; Male; Middle Aged; Ophthalmic Artery; Pandemics; Pneumonia, Viral; Pyrazoles; Pyridones; Risk Factors; SARS-CoV-2; Treatment Outcome; Venous Thrombosis	2020
[Toward the use of direct oral anticoagulants as a first line therapy in cancer-associated venous thromboembolism]. La Revue de medecine interne, 2020, Volume: 41, Issue:9 Topics: 4-Hydroxycoumarins; Administration, Oral; Anticoagulants; Clinical Trials as Topic; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Indenes; Medical Oncology; Neoadjuvant Therapy; Neoplasms; Prognosis; Pyrazoles; Pyridones; Risk Assessment; Venous Thromboembolism; Vitamin K	2020
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding. Annals of internal medicine, 2020, 08-18, Volume: 173, Issue:4 Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Recurrence; Venous Thromboembolism	2020
Rotational thromboelastometry in young, previously healthy patients with SARS-Cov2. Journal of clinical anesthesia, 2020, Volume: 67 Topics: Adult; Anticoagulants; Blood Coagulation Disorders; COVID-19; Enoxaparin; Heparin; Humans; Pyrazoles; Pyridones; Thrombelastography; Thrombosis	2020
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and haemostasis, 2020, Volume: 120, Issue:12 Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Male; Middle Aged; Pyrazoles; Pyridones; SARS-CoV-2; Survival Analysis	2020
Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. International journal of clinical practice, 2021, Volume: 75, Issue:10 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Pyrazoles; Pyridones; Retrospective Studies; Venous Thromboembolism; Venous Thrombosis	2021
Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. Mayo Clinic proceedings, 2021, Volume: 96, Issue:11 Topics: Enoxaparin; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Pancreatic Neoplasms; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Severity of Illness Index; United States; Venous Thrombosis	2021
New generation oral anticoagulant apixaban enhances embryo implantation by increasing integrin β3 expression in rats: A pilot study. JBRA assisted reproduction, 2022, 11-09, Volume: 26, Issue:4 Topics: Animals; Anticoagulants; Embryo Implantation; Enoxaparin; Female; Integrin beta3; Pilot Projects; Pregnancy; Rats	2022
An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. Journal of clinical pharmacology, 2022, Volume: 62, Issue:11 Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pilot Projects; Pyrazoles; Pyridones; Thrombocytopenia; Thrombosis	2022
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? Journal of infection in developing countries, 2022, 06-30, Volume: 16, Issue:6 Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Mannitol; Nervous System Diseases; Piracetam; Pyrazoles; Pyridones; Retrospective Studies; SARS-CoV-2	2022
Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. The Journal of urology, 2022, Volume: 208, Issue:4 Topics: Aftercare; Anticoagulants; Enoxaparin; Humans; Patient Discharge; Prospective Studies; Pyrazoles; Pyridones; Quality Improvement; Venous Thromboembolism; Venous Thrombosis	2022
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. Journal of thrombosis and haemostasis : JTH, 2023, Volume: 21, Issue:1 Topics: Anticoagulants; Catheters; Enoxaparin; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridones; Rivaroxaban; Thrombin; Thrombosis	2023
Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. Gynecologic oncology, 2023, Volume: 172 Topics: Anticoagulants; Canada; Enoxaparin; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Laparotomy; Postoperative Complications; Venous Thromboembolism	2023
Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy. BJU international, 2023, Volume: 132, Issue:4 Topics: Anticoagulants; Cystectomy; Enoxaparin; Humans; Robotics; Venous Thromboembolism	2023